0.00Open0.75Pre Close0 Volume129 Open Interest20.00Strike Price0.00Turnover266.55%IV8.59%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.75Extrinsic Value100Contract SizeAmericanOptions Type-0.3288Delta0.1132Gamma28.08Leverage Ratio-0.6420Theta-0.0002Rho-9.23Eff Leverage0.0043Vega
Jasper Therapeutics Stock Discussion
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
14 of 15 participants enrolled achieved a clinical response
10 of 12 participants in the 120mg cohort achieved a complete response
No serious adverse events; no grade 3 or higher adverse events reported
Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort
Company to host conference call and webinar today at 8:00 ...
Microsoft $Microsoft (MSFT.US)$ (office currently has nearly 400 million users, OficARPU increases after the acquisition of OpenA and Azurez-related...
No comment yet